Spray Drying Nanosuspensions: A Novel Approach for Improved Bioavailability in Solid Dosage Forms
Are you ready to take your drug formulations to the next level? Don’t miss this game-changing presentation on how combining Wet Bead Milling with Spray Dried Dispersion—also known as spray drying of API nanosuspensions—can revolutionize your approach to drug delivery and improve the outcomes of your clinical trials. This innovative approach has gained significant attention in the pharmaceutical industry for its ability to boost solubility and bioavailability, increase product stability, optimize drug release, improve formulation performance, and accelerate development timelines. Key presentation topics include:
- The science behind wet bead milling
- Spray drying of API nanosuspensions
- Benefits of combining the two techniques
- Impact on the conduct and outcome of clinical trials
- A case study
Join us to discover how our expertise in spray-drying nanosuspended APIs can help make your clinical trials more efficient, effective, and reliable. We look forward to seeing you there!
Altasciences
-
Country/Region:Canada
-
Founded:1995
-
On CPHI since:2015
-
Certificates:3
-
Employees:1000 - 4999
Other Content from Altasciences (2)
-
News Altasciences acquires Sinclair Research and continues to expand pre-clinical platform
Laval, Quebec, January 4, 2022 – Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the U.S. -
Brochure Altasciences Integrated Drug Development Services
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach from lead candidate selection to clinical proof of concept.